NIPH Clinical Trials Search

Preventive effects of Eicosapentaenoic acid (EPA) on stroke recurrence and a symptom state in chronic stroke patients with dyslipidemia.

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Chronic stroke patients with dyslipidemia
Date of first enrollment	2009/01/01
Target sample size	100
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	pretreatment(Aspirin100mg/day) Eicosapentaenoic Acid ethyl ester 1800mg/day is added on pretreatment(Aspirin100mg/day)

Outcome(s)

Primary Outcome	Endothelial function(FMD:Flow Mediated Dilation)
Secondary Outcome	1.IMT(intima Media Thickness) 2.Endothelial function(ADMA:Asymmetric Dimethyl Arginine) 3.Inflammatory markers(hs-CRP:High sensitivity C-reactive protein) 4.Adiponectin 5.Serum lipid(TC,HDL-C,TG) 6.Plasma fatty acid(EPA/AA ratios)

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	85years-old
Gender	Male and Female
Include criteria
Exclude criteria	Following patients will be excluded from this study 1.SBP>=180mmHg or DBP>=110 2.Patirnts who are bleeding (Hemophilia, intracranial bleeding, Gastrointestinal bleeding, Urinary tract bleeding, Hemophysis, Vitreous hemorrhage) 3.Patients with known bleeding disorders or a predisposing condition 4.Severe liver or renal dysfunction 5.Malignancy 6.Scheduling the operation 7.Past history of severe adverse effect by Aspirin or Eicosapentaenoic Acid ethyl ester 8.Patients who are inadequate by physician's decision